Tauriga Sciences Inc. Appoints Robert Millman, JD as a Member of the Company's Business Advisory Board

Tauriga logo

NEW YORK, May 5, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company with a pending acquisition in the cannabis space, today announced the appointment of Robert Millman, JD ("Mr. Millman") to the Company's Business Advisory Board. Mr. Millman is an experienced portfolio manager focused on growth businesses in the biotechnology, specialty pharma, and medical technologies spaces. He currently serves as a Managing Director of the prestigious life sciences fund MPM Capital and is also an experienced IP ("patent") attorney. Mr. Millman is contributing his considerable individual expertise and is not representing MPM Capital in his capacity as a Business Advisory Member. Moreover, he has personally invested in Tauriga Sciences based on his confidence in their strategic plan. With this appointment of Mr. Millman, Tauriga's business advisory board is now comprised of eight highly qualified members.

The Business Advisory Board's mandate is to assist the Company with management and guidance, developing strategies for funding, improving capital structure, identifying new opportunities and technical expertise in the development of the Company's businesses. Mr. Millman will specifically focus on evaluating opportunities in the life sciences space and introducing the Company to additional institutional investors.

Tauriga's CEO Dr. Stella M. Sung stated, "The appointment of Robert Millman to Tauriga's business advisory board is a meaningful addition to the Company at this time. Mr. Millman has co-founded and built several leading biotechnology companies using his considerable skill in identifying potentially revolutionary technology and in negotiating key license agreements. Moreover, he was one of the leading patent lawyers in the early days of the genomics revolution. I believe these skills and experiences are absolutely applicable to the significant market opportunities in the natural medicine sector. The Company continues to make significant progress on a number of fronts and will work closely with Mr. Millman to build its long term fundamentals."

Commenting on his advisory board appointment, Mr. Robert Millman expressed, "It is a pleasure to work with an exciting micro cap company such as Tauriga Sciences and its potential to create shareholder value through executing on its present opportunities. I have enjoyed working with Dr. Sung in the past and look forward to assisting her in building a valuable company."

PERSONAL BIO for Robert Millman, Age 53

Robert Millman began working with the prestigious biotechnology fund MPM Capital in 2007. Since joining MPM, he has helped form and served as the start-up IP Counsel of several MPM portfolio companies, including Epizyme, iPieran, and Verastem. Most recently, Mr. Millman founded, and led as start-up President, CoStim Pharmaceuticals, one of MPM's newest investments focusing on the immunotherapy of cancer. Mr. Millman has also served as an IP counsel for several important portfolio companies during funding, development or transactions, including Peplin, Syndax, and Valeritas. Prior to joining MPM Capital, Mr. Millman was the Chief IP Counsel for Alnylam Pharmaceuticals Inc., the Chief IP Counsel at Infinity Pharmaceuticals, Inc., the Chief IP Counsel at Celera Genomics, and a Patent Counsel at Millennium Pharmaceuticals, Inc.

Earlier in his career, Mr. Millman was an Associate at Morrison and Foerster LLP and a patent agent/specialist at Sterne, Kessler Goldstein and Fox, LLP. Mr. Millman received his J.D. degree from the Washington College of Law at The American University, an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside.

(http://www.mpmcapital.com/team/team-detail/robert-millman)

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On March 10, 2014, Tauriga signed a definitive agreement to acquire a California based topical cannabis cream company. Please visit the Company's corporate website at (www.tauriga.com).

NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

CONTACT: Tauriga Sciences, Inc.: Dr. Stella M. Sung, Chairman and Chief Executive Officer Tauriga Sciences, Inc. www.tauriga.com San Diego: + 1-858-353-5749 Montreal: + 1-514-840-3697 Email: ssung@tauriga.com

Source:Tauriga Sciences Inc